

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Multiple Technology Appraisal (MTA)

Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor

Expert statement declaration form

Please sign and return by email to:
Jeremy.Powell@nice.org.uk

If email is not possible, please return by fax to Jeremy Powell
on 020 7061 9830

or by post to: NICE, MidCity Place, 71 High Holborn, London WC1V 6NA

I confirm that:

- I agree with the content of the submission from the **National Rheumatoid Arthritis Society** and consequently I will not be submitting a personal statement.

Name: Mrs Ailsa Bosworth

Signed: 

Date: 22.1.10